metabolic condition.

11. The method of claim 10, wherein the metabolic condition is type 2 diabetes, obesity, insulin resistant states, nonalcoholic steatohepatitis (NASH), or nonalcoholic fatty liver disease (NAFLD).

12. The method of any of the preceding claims, wherein determining the expression profile comprises determining the mRNA expression level.

13. The method of claim 12, wherein the mRNA expression level is measured using qRT-PCR.

14. The method of any one of the preceding claims, wherein the change in expression level of the set of genes in the test sample is at least about a 1.5 fold difference as compared to the control sample.

15. A method of monitoring effectiveness of an insulin sensitizer therapy given to a patient comprising the steps of

a) determining the expression profile of a set of genes selected from the group consisting of the genes of Table 1 in a test sample of whole blood taken from the patient,

b) comparing the expression profile of the set of genes to the expression profile of the set of genes from reference sample of whole blood taken from the patient prior to treatment with the insulin sensitizer, and

c) determining that the therapy is effective when the expression profile of the genes in the test sample is more similar than the expression profile of the genes in the reference sample to the expression profile of non-insulin resistant control sample.

~~16. The methods substantially as hereinbefore described, especially with reference to the foregoing examples.~~